EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL)

Izel Okcu iD, Yucai Wang iD, Zhuo Li, Launia J White, Patrick B Johnston, Allison C Rosenthal, Jonas Paludo, Rebecca L King, Thomas E Witzig iD, Thomas M Habermann iD, Grzegorz S Nowakowski, Han W Tun

Hematological Oncology · 2026-03 · 44 (2)

DOI: 10.1002/hon.70182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 07.03.2026. Verfasst von Izel Okcu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Neoplasm Recurrence, Local, Lymphoma, B-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

162 patients with relapsed secondary central nervous system lymphoma (R‐SCNSL) (median age, 65 years; male, 59.9%) including central nervous system (CNS)‐only ( n = 120) and concomitant CNS/systemic relapse ( n = 42) were retrospectively analyzed. Overall, 21.9% of patients were classified as high risk according to the CNS International Prognostic Index (CNS‐IPI). Several biological and clinical features were significantly associated with leptomeningeal involvement, including double‐ or triple‐hit (DHL/THL) status, MYC rearrangement, negative BCL6 expression by IHC, bone marrow involvement, and concomitant R‐SCNSL. Multivariable analysis showed that leptomeningeal involvement independently predicted inferior OS and was associated with a 98% increase in the hazard of death compared with parenchymal relapse (HR = 1.98, 95% CI: 1.20–3.26, p = 0.008). Based on anatomical localization, R‐SCNSL was classified into four subtypes: parenchymal‐only involvement (parenchymal‐CNS [P‐CNS], 68/42%) and parenchymal involvement plus systemic relapse (parenchymal‐concomitant [P‐concomitant], 17/10.5%); and leptomeningeal with or without parenchymal involvement (leptomeningeal‐CNS [LM‐CNS], 52/32.1%) and leptomeningeal with systemic relapse (leptomeningeal‐concomitant [LM‐concomitant], 25/15.4%). This anatomical classification significantly impacted OS and PFS ( p < 0.001). Two‐year OS and PFS were 58.2% and 29.1% for P‐CNS, 32.4% and 17.7% for P‐concomitant, 22% and 13.9% for LM‐CNS, and 7.1% and 0% for LM‐concomitant, respectively. ASCT showed a trend toward improved survival among patients with a response (CR/PR) in a 4‐month landmark analysis. These findings support the clinical application of the anatomical classification in the management of R‐SCNSL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsNeoplasm Recurrence, LocalLymphoma, B-CellHumansMaleAgedFemaleMiddle AgedRetrospective StudiesPrognosisAdultAged, 80 and over

Stichwörter der Autor:innen

CNS relapsediffuse large B‐cell lymphomahigh grade B‐cell lymphomaleptomeningeal involvementparenchymal involvement

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Internal Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, USA.
  • Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Izel Okcu, Yucai Wang, Thomas E Witzig, Thomas M Habermann

Förderung

  • Mayo Clinic

Zitieren

APA

Okcu, I., Wang, Y., Li, Z., White, L. J., Johnston, P. B., Rosenthal, A. C., Paludo, J., King, R. L., Witzig, T. E., Habermann, T. M., Nowakowski, G. S., & Tun, H. W. (2026). Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL). Hematological Oncology, 44(2). https://doi.org/10.1002/hon.70182

Vancouver

Okcu I, Wang Y, Li Z, White LJ, Johnston PB, Rosenthal AC, et al. Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL). Hematological Oncology. 2026;44(2). doi:10.1002/hon.70182

BibTeX
@article{Okcu2026,
  author = {Okcu, Izel and Wang, Yucai and Li, Zhuo and White, Launia J and Johnston, Patrick B and Rosenthal, Allison C and Paludo, Jonas and King, Rebecca L and Witzig, Thomas E and Habermann, Thomas M and Nowakowski, Grzegorz S and Tun, Han W},
  title = {Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL)},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {2},
  doi = {10.1002/hon.70182}
}
Kostenlos starten →